Table S4. Univariate and multivariate prognostic analysis on BCSS in training group of patients.
| Characteristics | Univariate | Multivariate | |||||
| OR | 95% CI | P | OR | 95% CI | P | ||
| BCSS, breast cancer-specific survival; IDC, invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal receptor 2; TNBC, triple negative breast cancer; BCS, breast conversing surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; OR, odds ratio; 95% CI, 95% confidence interval. | |||||||
| Age (year) | 0.618 | − | |||||
| <50 | 1.00 | ||||||
| ≥50 | 0.86 | 0.49−1.53 | |||||
| Menstruation | 0.916 | − | |||||
| Pre-menopausal | 1.00 | ||||||
| Post-menopausal | 1.03 | 0.58−1.83 | |||||
| Histology | 0.900 | − | |||||
| IDC | 1.00 | ||||||
| Non-IDC | 1.10 | 0.27−4.52 | |||||
| Grade | 0.002 | 0.029 | |||||
| I | 0.21 | 0.11−0.53 | <0.001 | 0.27 | 0.19−0.61 | ||
| II | 0.34 | 0.19−0.62 | <0.001 | 0.43 | 0.24−0.80 | 0.008 | |
| III | 1.00 | 1.00 | |||||
| ER | <0.001 | 0.059 | |||||
| Negative | 1.00 | 1.00 | |||||
| Positive | 0.28 | 0.15−0.50 | 0.47 | 0.22−1.03 | |||
| PR | <0.001 | 0.164 | |||||
| Negative | 1.00 | 1.00 | |||||
| Positive | 0.24 | 0.12−0.48 | 0.52 | 0.21−1.30 | |||
| Ki67 | 0.961 | − | |||||
| <14% | 1.00 | ||||||
| ≥14% | 1.02 | 0.45−2.30 | |||||
| HER2* | 0.032 | 0.011 | |||||
| HER2-zero | 1.00 | 1.00 | |||||
| HER2-low | 0.67 | 0.28−0.98 | 0.038 | 0.55 | 0.31−0.89 | 0.025 | |
| HER2-amplified | 0.32 | 0.14−0.92 | 0.033 | 0.28 | 0.11−0.70 | 0.007 | |
| Primary phenotype | <0.001 | − | |||||
| Luminal-A | 0.02 | 0.01−0.23 | <0.001 | ||||
| Luminal-B/HER2-negative | 0.27 | 0.14−0.51 | <0.001 | ||||
| Luminal-B/HER2-positive | 0.04 | 0.01−0.31 | 0.002 | ||||
| HER2-amplified | 0.35 | 0.14−0.86 | 0.022 | ||||
| TNBC | 1.00 | ||||||
| Breast surgery | 0.204 | − | |||||
| Mastectomy | 1.00 | ||||||
| BCS | 2.14 | 0.67−6.88 | |||||
| Axillary surgery | 0.638 | − | |||||
| SLNB | 1.00 | ||||||
| ALND±SLNB | 1.41 | 0.34−5.86 | |||||